Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Jun 29, 2015 12:24pm
72 Views
Post# 23877256

RE:RE:RE:RE:RE:RE:RE:COULD NOT ZENITH DO THIS??

RE:RE:RE:RE:RE:RE:RE:COULD NOT ZENITH DO THIS??JK, I looked back through your posts since around May 14th and see nothing other than speculation/rumor spread by your regarding the Zenith patent issue. I you feel that you have posted something concrete in the past about this, please re-post. Personally, I agree with San Fran that non of us on this board have been privy to the information from the company regarding the exact turn of events surrounding the patent issue. Maybe I missed something that the company said or that you posted. So if so, please step up and re-post or provide a link.

BDAZ

Jkj193741 wrote: Bear, I am not so negative but. In the case of Zenith I do not stand corrected. I will stand corrected when I see the new IND filed as committed. Also I have discussed the patent issue many times. One simply needs to ask RVX which two long time employees left in the last couple of years and then take a look at their C.V' wherein they list their claim to at least partial ownership in the discovery of ZEN 3365. Or in the alternative take a look at my prior posts on this topic. As to the benefit Zenith will receive from the HEPALINK deal, I would like to see the details of the proposed amendment that has been announced to the royalty share and other Zenith matters. These are simply the thoughts of an old country boy. That being the case, I would not get too excited about the importance of my so called " negative post." For Zenith to have had spent the funds to develope Zen3365; design and have approved and funded a trial for that agent, and then to withdraw the trial FO " business developed" is ,to say the least unusual. Why does not someone ask RVX or Zenith who held the competing patents, and see if they would enlighten us retail shareholders. IMHO Thanks, jk


Bullboard Posts